Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ExeVir Bio

http://vib.be/

Latest From ExeVir Bio

Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised

ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.

Europe Coronavirus COVID-19

Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe. 

Financing Innovation

Fund+ Makes Moves In Europe With Further Growth On The Cards

In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.

VC Playbook Strategy

Coronavirus Notebook: A UK Catapult, A Russian Vaccine, And A Cuban Therapy

The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.

Europe United Kingdom
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register